artificial immune modulation (aim) platform Search Results


artificial immune modulation (aim) act system  (NexImmune)
90
NexImmune artificial immune modulation (aim) act system
Artificial Immune <t>Modulation</t> Adoptive Cell Therapy <t>(AIM</t> <t>ACT).</t> (1) Leukapheresis material is collected from a patient with infection ( e.g. , EBV, HTLV-1, HPV, and HIV). (2) The CD8 + T cells are enriched for using paramagnetic AIM nanoparticles that function as artificial APCs (aAPCs) to expand CD8 + T cells specific for immunodominant viral antigens. (3) After 14 days expansion, AIM nanoparticles are washed out and the AIM ACT is ready to be infused into patients.
Artificial Immune Modulation (Aim) Act System, supplied by NexImmune, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/artificial+immune+modulation+(aim)+platform/neximmune++md+biotech+center/pmc09822776-47-2-8
Average 90 stars, based on 1 article reviews
artificial immune modulation (aim) act system - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Artificial Immune Modulation Adoptive Cell Therapy (AIM ACT). (1) Leukapheresis material is collected from a patient with infection ( e.g. , EBV, HTLV-1, HPV, and HIV). (2) The CD8 + T cells are enriched for using paramagnetic AIM nanoparticles that function as artificial APCs (aAPCs) to expand CD8 + T cells specific for immunodominant viral antigens. (3) After 14 days expansion, AIM nanoparticles are washed out and the AIM ACT is ready to be infused into patients.

Journal: Frontiers in Medicine

Article Title: AIM™ platform: A new immunotherapy approach for viral diseases

doi: 10.3389/fmed.2022.1070529

Figure Lengend Snippet: Artificial Immune Modulation Adoptive Cell Therapy (AIM ACT). (1) Leukapheresis material is collected from a patient with infection ( e.g. , EBV, HTLV-1, HPV, and HIV). (2) The CD8 + T cells are enriched for using paramagnetic AIM nanoparticles that function as artificial APCs (aAPCs) to expand CD8 + T cells specific for immunodominant viral antigens. (3) After 14 days expansion, AIM nanoparticles are washed out and the AIM ACT is ready to be infused into patients.

Article Snippet: With the Artificial Immune Modulation (AIM) ACT system, NexImmune may overcome many of these challenges to develop cellular therapies for patients with virally driven diseases ( ).

Techniques: Infection

HLA-A2 restricted peptides from viral driven diseases tested in the AIM ACT system.

Journal: Frontiers in Medicine

Article Title: AIM™ platform: A new immunotherapy approach for viral diseases

doi: 10.3389/fmed.2022.1070529

Figure Lengend Snippet: HLA-A2 restricted peptides from viral driven diseases tested in the AIM ACT system.

Article Snippet: With the Artificial Immune Modulation (AIM) ACT system, NexImmune may overcome many of these challenges to develop cellular therapies for patients with virally driven diseases ( ).

Techniques:

Phenotype of the T cells on day 0, before expansion, and on day 14 after enrichment and expansion for EBV antigen specific T cells using the AIM ACT system. (A,B) Results are shown from two healthy donors. After completion of expansion, T cells from each run were taken for phenotyping memory cell populations by staining for CD62L vs CD45RA. The naïve and stem cell-like memory cells were further distinguished by CD95 expression. The pie charts show the distribution of memory T cell subsets at day 0 and day 14 of the process. Central memory T cells (Tcm), effector memory T cells (Tem), effector memory T cells re-expressing CD45RA (Temra), stem cell-like memory T cells (Tscm), naïve T cell (Tn).

Journal: Frontiers in Medicine

Article Title: AIM™ platform: A new immunotherapy approach for viral diseases

doi: 10.3389/fmed.2022.1070529

Figure Lengend Snippet: Phenotype of the T cells on day 0, before expansion, and on day 14 after enrichment and expansion for EBV antigen specific T cells using the AIM ACT system. (A,B) Results are shown from two healthy donors. After completion of expansion, T cells from each run were taken for phenotyping memory cell populations by staining for CD62L vs CD45RA. The naïve and stem cell-like memory cells were further distinguished by CD95 expression. The pie charts show the distribution of memory T cell subsets at day 0 and day 14 of the process. Central memory T cells (Tcm), effector memory T cells (Tem), effector memory T cells re-expressing CD45RA (Temra), stem cell-like memory T cells (Tscm), naïve T cell (Tn).

Article Snippet: With the Artificial Immune Modulation (AIM) ACT system, NexImmune may overcome many of these challenges to develop cellular therapies for patients with virally driven diseases ( ).

Techniques: Staining, Expressing

AIM ACT cells selected on 6 EBV peptides produce a polyfunctional response upon antigen-specific restimulation. Intracellular cytokine staining was run on EBV antigen-specific E+E cells from 2 healthy donors. Cells were left unstimulated or were restimulated with nanoparticles loaded with one of the six EBV peptides. Representative plots show the expression of functional markers by CD8 + T cells from EBV Donor 2 when (A) left unstimulated or when (B) stimulated with BRLF1 loaded nanoparticles. The cumulative percentage of CD8 + T cells from (C) EBV Donor 1 and (D) EBV Donor 2 that express each functional marker in response to stimulation with peptide loaded nanoparticles. Conditions were run in duplicate wells.

Journal: Frontiers in Medicine

Article Title: AIM™ platform: A new immunotherapy approach for viral diseases

doi: 10.3389/fmed.2022.1070529

Figure Lengend Snippet: AIM ACT cells selected on 6 EBV peptides produce a polyfunctional response upon antigen-specific restimulation. Intracellular cytokine staining was run on EBV antigen-specific E+E cells from 2 healthy donors. Cells were left unstimulated or were restimulated with nanoparticles loaded with one of the six EBV peptides. Representative plots show the expression of functional markers by CD8 + T cells from EBV Donor 2 when (A) left unstimulated or when (B) stimulated with BRLF1 loaded nanoparticles. The cumulative percentage of CD8 + T cells from (C) EBV Donor 1 and (D) EBV Donor 2 that express each functional marker in response to stimulation with peptide loaded nanoparticles. Conditions were run in duplicate wells.

Article Snippet: With the Artificial Immune Modulation (AIM) ACT system, NexImmune may overcome many of these challenges to develop cellular therapies for patients with virally driven diseases ( ).

Techniques: Staining, Expressing, Functional Assay, Marker